Next Article in Journal / Special Issue
Patient-Specific iPSC-Derived RPE for Modeling of Retinal Diseases
Previous Article in Journal
Sick Leave and Factors Influencing Sick Leave in Adult Patients with Atopic Dermatitis: A Cross-Sectional Study
Previous Article in Special Issue
Potential Role of Induced Pluripotent Stem Cells (IPSCs) for Cell-Based Therapy of the Ocular Surface
Article Menu

Export Article

Open AccessReview
J. Clin. Med. 2015, 4(4), 548-566; doi:10.3390/jcm4040548

Using iPS Cells toward the Understanding of Parkinson’s Disease

1
Institute for Biomedicine of the University of Barcelona (IBUB), Barcelona Science Park, Barcelona 08028, Spain
2
Department of Molecular and Translational Medicine, Fibroblast Reprogramming Unit, University of Brescia, Brescia 25123, Italy
3
Control of Stem Cell Potency Group, Institute for Bioengineering of Catalonia (IBEC), Barcelona 08028, Spain
4
Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona 08010, Spain
5
Center for Networked Biomedical Research on Bioengineering, Biomaterials and Nanomedicine (CIBER-BBN), Madrid 28029, Spain
6
Center of Regenerative Medicine in Barcelona, Dr. Aiguader 88, Barcelona 08003, Spain
*
Author to whom correspondence should be addressed.
Academic Editor: Michael J. Edel
Received: 23 October 2014 / Revised: 10 February 2015 / Accepted: 10 February 2015 / Published: 30 March 2015
(This article belongs to the Special Issue iPS Cells for Modelling and Treatment of Human Diseases)
View Full-Text   |   Download PDF [285 KB, uploaded 30 March 2015]   |  

Abstract

Cellular reprogramming of somatic cells to human pluripotent stem cells (iPSC) represents an efficient tool for in vitro modeling of human brain diseases and provides an innovative opportunity in the identification of new therapeutic drugs. Patient-specific iPSC can be differentiated into disease-relevant cell types, including neurons, carrying the genetic background of the donor and enabling de novo generation of human models of genetically complex disorders. Parkinson’s disease (PD) is the second most common age-related progressive neurodegenerative disease, which is mainly characterized by nigrostriatal dopaminergic (DA) neuron degeneration and synaptic dysfunction. Recently, the generation of disease-specific iPSC from patients suffering from PD has unveiled a recapitulation of disease-related cell phenotypes, such as abnormal α-synuclein accumulation and alterations in autophagy machinery. The use of patient-specific iPSC has a remarkable potential to uncover novel insights of the disease pathogenesis, which in turn will open new avenues for clinical intervention. This review explores the current Parkinson’s disease iPSC-based models highlighting their role in the discovery of new drugs, as well as discussing the most challenging limitations iPSC-models face today. View Full-Text
Keywords: induced pluripotent stem cells; Parkinson’s disease; Leucine-rich repeat kinase 2 (LRRK2); dopaminergic neurons induced pluripotent stem cells; Parkinson’s disease; Leucine-rich repeat kinase 2 (LRRK2); dopaminergic neurons
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Torrent, R.; De Angelis Rigotti, F.; Dell'Era, P.; Memo, M.; Raya, A.; Consiglio, A. Using iPS Cells toward the Understanding of Parkinson’s Disease. J. Clin. Med. 2015, 4, 548-566.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
J. Clin. Med. EISSN 2077-0383 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top